ArticleJournal of clinical medicine research2026
Polypharmacy and Dose Adjustment in Chronic Kidney Disease: A Cross-Sectional Study.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a significant global health issue, primarily due to the rise in diabetes mellitus. This study aims to analyze the medications used in CKD patients with varying severity, focusing on dose adaptation. Methods: This was a retrospective observational analysis of patients with CKD from various causes. CKD staging followed the 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, and all medications given during the study were recorded, including documentation of dose adjustments due to reduced kidney function. Results: The study included 106 CKD patients. A total of 209 active medications were examined, with an average of 11.2 ± 4.8 substances used per patient. The average number of medications did not differ significantly across CKD stages. Dose adjustments for reduced kidney function were required in 40.19% of patients, who received an average of 5.4 ± 4.6 medications requiring dose reduction, with appropriate adjustments made for 4.6 ± 2.2 substances on average. Conclusions: The study found that polypharmacy is present in all stages of CKD, and the significant rate of dose adjustments suggests that physicians are aware of the need to manage medications for CKD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.